New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Fractyl Health, Inc.

Contributing Author

Recent Articles by Fractyl Health, Inc.

Oct-07	Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity GUTS GlobeNewswire
Sep-26	Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock GUTS GlobeNewswire
Sep-26	Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita Maintained Weight Loss After GLP-1 Discontinuation GUTS GlobeNewswire
Sep-03	Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth GUTS GlobeNewswire
Aug-12	Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates GUTS GlobeNewswire
Aug-07	Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares GUTS GlobeNewswire
Aug-06	Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference GUTS GlobeNewswire
Aug-06	Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering GUTS GlobeNewswire
Aug-05	Fractyl Health Announces Proposed Public Offering GUTS GlobeNewswire
Aug-05	Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure GUTS GlobeNewswire
Jun-23	Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy GUTS GlobeNewswire
Jun-23	Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models GUTS GlobeNewswire
Jun-18	Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing GUTS GlobeNewswire
Jun-13	Fractyl Health to Present New Preclinical Data from its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions GUTS GlobeNewswire
Jun-04	Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide GUTS GlobeNewswire
May-19	Fractyl Health Advances Rejuva Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes GUTS GlobeNewswire
May-17	Fractyl Health Unveils New Rejuva Smart GLP-1 Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 GUTS GlobeNewswire
May-13	Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates GUTS GlobeNewswire
May-06	Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference GUTS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.